Shanghai, China – On October 30, experts from Chinese Society of Biotechnology visited Shanghai MicroPort Medical (Group) Co ("MicroPort®") for survey and investigation. Led by four academicians including biotechnology specialist Shengli Yang, the team hosted a panel discussion in MicroPort®. MicroPort® Chairman and Chief Executive Officer Dr. Zhaohua Chang and other members of MicroPort® management received the team.
Entrusted by the National Development and Reform Commission of the State Council, the research group of China Society of Biotechnology recently visited Shanghai Zhangjiang biological medicine industrial base for investigation. As a leading innovative company in biomedical-related industry based in Zhangjiang Hi-tech Park, MicroPort® has been selected as a key site for the survey. The team was shown around MicroPort® Self-Experience Center and briefed MicroPort®'s technology innovation, product clinical application, corporate vision and future development plan.
During the panel discussion, the four academicians, based on their respective fields of study, exchanged ideas and had in-depth discussion with MicroPort® staff in terms of material science, patents, technological processes, the combination of production, education and research, and medical insurance policies. The team fully recognized MicroPort®'s achievements, and noted that the relevant government departments will provide more support to China's innovative enterprises to drive their technology innovation and development.